Importantly, EPO administration 1 hour after injury was sufficient to reduce IL-1β to sham levels, highlighting EPO’s ability to modulate neuroinflammation early and robustly after diffuse TBI, as reported in models of focal brain injury [26-29]. Here, IL1B is linked to injury.